Predictors of Success of IUI in Unexplained Infertility

Study Overview
=================
Brief Summary
-----------------
Superovulation will be conducted with 100 mg of oral clomiphene citrate (Clomifene; Young Poong Pharmaceutical, Incheon, Korea) for 5 days starting on day 3 of the menstrual cycle, followed by daily injection of 150 IU of human menopausal gonadotropin (hMG;Menogon; FerringPharamceutical Co, Germany). When more than 2 dominant follicles reached a diameter of 17 mm or the urinary specimen showed positive results for luteinizing hormone (LH) surge, 5000 IU of hCG (Pregnyl; Organon, Oss, the Netherlands) was injected intramuscularly.

Detailed Description
-----------------
Superovulation will conducted with 100 mg of oral clomiphene citrate (Clomifene; Young Poong Pharmaceutical, Incheon, Korea) for 5 days starting on day 3 of the menstrual cycle, followed by daily injection of 150 IU of human menopausal gonadotropin (hMG;Menogon; FerringPharamceutical Co, Germany). When more than 2 dominant follicles reached a diameter of 17 mm or the urinary specimen showed positive results for luteinizing hormone (LH) surge, 5000 IU of hCG (Pregnyl; Organon, Oss, the Netherlands) was injected intramuscularly. Successful pregnancy after IUI was confirmed by ultrasound as one or more visible gestational sacs in the uterine cavity.

Official Title
-----------------
Factors Affecting Success of IUI in Women With Unexplained Infertility

Conditions
-----------------
Assisted Reproductive Techniques

Intervention / Treatment
-----------------
* Device: Intrauterine insemenation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: These patients had at least 1 tube patent there were no significant intrauterine or pelvic abnormalities demonstrated on pelvic-abdominal ultrasonography, hysteroscopy, and/or laparoscopy serum follicular stimulating hormone (FSH) level of12 mIU/mL or less Exclusion Criteria: A woman's age of more than 40 years, ovarian cyst detected in the ultrasound examination uterine lesions such as submucosal leiomyoma, and a previous diagnosis of moderate to severe pelvic endometriosis. women with body mass index > 35 kg/m2, PCOS/anovulatory patients signs of hyperandrogenemia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Pregnant<br>women with positive serum beta HCG done 14 days after Intrauterine insemenation | Device: Intrauterine insemenation<br>* Semen preparation processing hen intrauterine transfer after 24 hours of HCG triggering of ovulation<br>|
| Active Comparator: Nonpregnant<br>women with negative serum beta HCG done 14 days after Intrauterine insemenation | Device: Intrauterine insemenation<br>* Semen preparation processing hen intrauterine transfer after 24 hours of HCG triggering of ovulation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| chemical pregnancy rate |  | 14 days after IUI | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IUI, Pregnancy rate, predictors